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Scedosporium apiospermum is an emerging opportunistic fungus that can cause localized infection in
healthy hosts or severe disseminated disease in immunocompromised hosts. Most cases are reported in
Western Europe, Australia, and North America. We report a 52-year-old immunocompetent Taiwanese
woman who presented with a 6-year history of recurrent asymptomatic papulonodular lesions on her
right foot after minor trauma. Deep fungal infection caused by Scedosporium sp. was diagnosed after
a skin biopsy with fungal culture of the skin specimen. She underwent two surgical excisions, each
followed by a 4-month course of oral itraconazole and intralesional injections of amphotericin B as well,
but similar lesions recurred at the same location 1 year later. She had another surgical excision and the
pathological ﬁndings showed mycetoma. The fungus was identiﬁed as S. apiospermum by PCR assay of
fungal culture specimen using the internal transcriber spacers (ITS1, similarity 99.4%; ITS2, similarity
100%) and the D1eD2 (similarity 99.0%) regions of the ribosomal operon. After 4 months of oral vor-
iconazole (400 mg/day), no recurrence was noted in the subsequent 2 years.
Copyright  2013, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Scedosporium apiospermum is an emerging opportunistic pathogen
that can cause either disseminated disease in immunocompro-
mised hosts or localized infection in immunocompetent hosts
through trauma or surgery.1 Localized infections mainly affect the
skin and soft tissue with extension to tendons, ligaments, and even
the bone. Disseminated diseases may result in septic arthritis,
pneumonia, endocarditis, meningitis, brain abscess, sinusitis,
and/or keratitis. S. apiospermum is characterized by its resistance to
commonly used antimycotic drugs, such as ketoconazole, itraco-
nazole, and amphotericin B.2e4 Most cases of mycetomatous
S. apiospermum infections have been reported in Western Europe,e no ﬁnancial or non-ﬁnancial
erials discussed in this article.
ion 1, Dongguang Road, East
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-L. Hsu).
iwanese Dermatological AssociatioAustralia, and North America.5 We report the ﬁrst Taiwanese pa-
tient with recurrent mycetomatous S. apiospermum infection suc-
cessfully treated by surgical excision and oral voriconazole.Case report
A 52-year-old Taiwanese woman came to our department due to
recurrent asymptomatic papulonodular lesions on her right foot for
6 years. Erythematous nodular lesions were ﬁrst noted on her right
dorsal foot in October 2005 after minor trauma. Deep fungal
infection caused by Scedosporium species was diagnosed after
a skin biopsy and fungal culture of the biopsy specimen. She un-
derwent two surgical excisions in October 2005 and April 2008,
each followed by a 4-month course of oral itraconazole (300 or
400 mg/day). In addition, she was advised to use local thermal
therapy by applying warm packs (w50C, 30 minutes/day) for 2
weeks after the second surgical excision. Intralesional injections of
amphotericin B at a concentration of 5 mg/mL (once every othern. Published by Elsevier Taiwan LLC. All rights reserved.
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August 2008. Magnetic resonance imaging of the right foot in
October 2008 revealed edema of the soft tissues around the second,
third, and fourth metatarsals, and ﬂexor tendons secondary to the
recent surgery, but there was no speciﬁc inﬁltration. Unfortunately,
similar lesions recurred at the same location in November 2009
(Figure 1A). She received another surgical excision in January 2010
(Figure 1B). Interconnected, twisted tubule-like ﬁbroconnective
tissue and yellow-brownish nodules within necrotic tissue were
found during the operation (Figure 1C). Pathologic examination of
the excised tissue showed features of mycetoma characterized by
discrete nodular aggregates of fungal hyphae in multiple large
abscesses in the reticular dermis surrounded by lymphocytes,
histiocytes, and neutrophils (Figure 2A and B). The hyphae were
further highlighted by periodic acideSchiff (PAS) (Figure 2C) and
Gomori methenamine silver (GMS) stains (Figure 2D). Fungal cul-
ture of the excised skin tissue yielded grayishewhite cotton-like
colonies (Figure 3A). Microscopic examination revealed septate
and branched hyphae with ovoid conidia born terminally on
branched conidiophores or laterally on hyphae (Figure 3B). The
fungus was identiﬁed to the species level S. apiospermum by PCR
assay of the fungus from the culture using the internal transcriber
spacers (ITS1, similarity 99.4%; ITS2, similarity 100%) and the
D1eD2 (similarity 99.0%) regions of the ribosomal operon (Table 1).
Treatment with oral voriconazole (400 mg/day) was initiated. Ele-
vated liver enzymes (glutamic oxaloacetic transaminase (GOT)/
glutamic pyruvic transaminase (GPT) ¼ 176/131 U/L), however,
were noted after 3 months, so voriconazole was held off for 1 week,
and then was resumed when liver function tests returned to
baseline level (GOT/GPT ¼ 45/44 U/L). After a 4-month course of
voriconazole, there was no recurrence in the subsequent 2 years
(Figure 4).Figure 1 Clinical manifestation and surgical ﬁndings. (A) Papulonodular lesions recurred
excision in January 2010. (C) Interconnected, twisted tubule-like ﬁbroconnective tissue andDiscussion
Serious infections caused by S. apiospermum have been increasingly
reported in recent years.6 The sexual phase of S. apiospermum is
Pseudallescheria apiosperma.7 Its occurrence is promoted in manure-
enriched or polluted environments, such as agricultural land, garden
soil, sewer or ditch mud, and polluted pond bottoms.8,9 Serious
infection is more common in temperate climates and less frequently
encountered in the tropics.8 S. apiospermum causes awide spectrum
of conditions, including mycetoma, colonization of the airways,
sinopulmonary infections, extrapulmonary localized infections, and
disseminated infections.1 The term “mycetoma” represents
a chronic, progressive, indolent mycosis characterized by tume-
faction (subcutaneous tissues become edematous), multiple drain-
ing sinuses, and extrusion of grains.Mycetoma can be caused by soil-
inhabiting bacteria (actinomycosis) or fungi (eumycetoma).1 In one
retrospective studyof 63 cases in the United States, S. apiospermum is
the most common fungal etiologic agent of mycetoma.10
Histopathologically, mycetoma shows nodular aggregates of
fungal hyphae, which are more easily demonstrated by PAS or GMS
stains. In tissue sections, S. apiospermum displays septate and
branched hyphae, and can be mistaken as Aspergillus, Fusarium, or
other species of black fungi.11 Kimura et al found that the combi-
nation of haphazardly branching hyphae and lemon-shaped con-
idia was the most useful feature to differentiate S. apiospermum
from other ﬁlamentous fungi in tissue.11
Diagnosis of S. apiospermum infection is conﬁrmed by culture of
the infected tissue. The colony typically looks light to brownish gray
with a mouse fur-like appearance in 1e2 weeks, but other mor-
phologically similar species can make the identiﬁcation of
S. apiospermum difﬁcult.12 In the present study, we applied PCR to
amplify the ITS1, ITS2, and D1eD2 regions of 26S rDNA.13 Theat the right dorsal foot in November 2009. (B) The patient received another surgical
yellowebrownish nodules within necrotic tissue were found during the operation.
Figure 2 Histopathological examination of mycetoma. (A) Mycetomawas characterized by discrete nodules surrounded by lymphocytes, histiocytes, and neutrophils in the reticular
dermis (H&E, scanning mode). (B) Aggregates of fungal hyphae were revealed in the large abscess (H&E, 100). The hyphae structures were further identiﬁed by (C) periodic acide
Schiff (100) and (D) Gomori methenamine silver stains (200).
Figure 3 Fungal culture and microscopic examination. (A) Fungal culture of the excised skin tissue yielded grayishewhite cottony colonies. (B) Microscopic examination revealed
septate and branched hyphae with ovoid conidia borne terminally on branched conidiophores or laterally on hyphae (Trypan blue stain, 200).
Table 1 PCR and sequence analysesa.
Target region Sequence similarity Sequence (50 to 30)
ITS1 99.4% TCCGTAGGTGAACCTGCGG
GCTGCGTTCTTCATCGATGC
ITS2 100% GCATCGATGAAGAACGCAGC
TCCTCCGCTTATTGATATGC
D1eD2 99.0% GCATATCAATAAGCGGAGGAAAAG
GGTCCGTGTTTCAAGACGG
a Sequence analyses of the internal transcriber spacers (ITS1, similarity 99.4%;
ITS2, similarity 100%) and the D1eD2 (similarity 99.0%) regions of the ribosomal
operon. Detailed information of primers and sequences are listed.
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for searching homologous sequences in public databases using the
BLASTN algorithm (http://www.ncbi.nlm.nih.gov/BLAST/). The
BLAST search hit best-scoring sequences from S. apiospermumwith
99.4% (ITS1), 100% (ITS2), and 99.0% (D1eD2) similarities.
Treatments of mycetomatous S. apiospermum infection include
surgical debridement and antifungal therapy.14,15 The former should
be applied if the lesion is localized.14 Antifungal therapy is considered
as a conservative treatment for those who are too weak to have sur-
gery or as an adjuvant treatment to surgery for refractorymycetoma.
S. apiospermum has very high levels of resistance to conventional
antifungal drugs.16 Among azoles tested for in vitro activity against
S. apiospermum, voriconazole has the most potent effect (MIC50,
0.25 mg/mL), followed by miconazole (MIC50, 0.5 mg/mL), and alba-
conazole (MIC50, 0.5e1 mg/mL).1,2,4,17 On the contrary, itraconazole
(MIC50, 4.5 mg/mL), ketoconazole (MIC50, 10.07 mg/mL), and ampho-
tericin B (MIC50, 4 mg/mL) showed poor antifungal activity.1,2,4,17Voriconazole is a broad-spectrum azole antifungal agent and
can be administered intravenously and orally with excellent bio-
availability.18 In a large series of 107 patients with scedosporiosis
treated with voriconazole (6 mg/kg of body weight intravenously
twice daily on Day 1, followed by 4 mg/kg intravenously twice daily
Figure 4 The clinical course and all treatments of recurrent mycetomatous infection from 2003 to March 2012.
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cessful therapeutic response was achieved in 57% of patients (me-
dian, 103 therapy days), with >98% of patients responding after
receiving >28 days of therapy.18 The best therapeutic responses
were seen for skin/subcutaneous (91%) or bone (79%) infections,
and the lowest for central nervous system infections (43%).18
Thereafter, sporadic cases with cutaneous S. apiospermum in-
fections successfully treated by oral or intralesional voriconazole
have also been reported.19,20 Although voriconazole is active
against a broad range of fungal pathogens, several adverse events
have been described, including reversible visual disturbances,
hallucinations, abdominal pain, and hepatitis, allergic skin re-
actions, and, less frequently, lymphadenopathy or pan-
cytopenia.18,20 Our patient had a transient elevation of liver
function tests after 3 months of voriconazole administration, which
recovered after the use of voriconazole was held for 1 week.
In summary, we report the ﬁrst Taiwanese patient with recur-
rent mycetomatous S. apiospermum infection. The infection of the
foot recurred twice after two surgical excisions plus oral itraco-
nazole therapy, and was ﬁnally controlled by another surgical
excision which was followed by a 4-month course of oral
voriconazole.
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